Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.
We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.
We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $315M
Founded date: 2019
Investors 3
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| - | Newpath Ma... | newpath.pa... |
| 07.08.2021 | GV | gv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.07.2021 | - | $315M | F-Prime Ca... |
Mentions in press and media 19
| Date | Title | Description |
| 10.06.2024 | Improved prime editing system makes gene-sized edits in human cells at therapeutic levels | Scientists at the Broad Institute of MIT and Harvard have improved a gene-editing technology that is now capable of inserting or substituting entire genes in the genome in human cells efficiently enough to be potentially useful for therapeu... |
| 25.01.2024 | Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis | - |
| 17.08.2023 | The 30 young leaders who are forging a new future for the healthcare industry in 2023 | Your browser does not support the video element. This story is available exclusively to Insider subscribers. Become an Insider and start reading now. A new generation of leaders is transforming the healthcare industry. They're developing ne... |
| 20.10.2022 | Prime Medicine pulls off $175M IPO and sketches out plans to reach the clinic | Prime Medicine projects it could begin the first human test of its gene-editing technology in 2024 with multiple programs on its heels in the following year. The biotech company now has $175 million in IPO cash to finance that research. In ... |
| 28.09.2022 | Prime Medicine is gearing up for a $200 million IPO. We dug through the biotech's 282-page filing to find 5 key takeaways about the company's plan to commercialize gene editing. | Keith Gottesdiener, the CEO of Prime Medicine. Prime Medicine This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Redeem now The gene-editing biotech Prime Medicine filed on Friday to go publ... |
| 20.07.2021 | Digital health news, funding roundup in the prior week; July 18 | With $150B already invested, VC is set to have another recording breaking year With $150B already invested, VC is set to have another recording breaking year. There was $75 billion invested across an estimated 4,302 deals in the second quar... |
| 14.07.2021 | Prime Medicine Raises $315M in Funding | Prime Medicine logo Prime Medicine, a Cambridge MA-based biotechnology company, raised $115M in Series A funding and $200M in Series B funding. The Series A round was led by ARCH Venture Partners with participation from F-Prime Capital, GV,... |
| 14.07.2021 | Prime Medicine launches with $315M | Prime Medicine, a nine-month-old gene editing company, has announced its launch with $315 million in funding. The financing comprised a $115 million Series A and a $200 million Series B backed by investors including Arch Venture Partners, F... |
| 14.07.2021 | Prime Medicine raises $315M to fuel ‘search-and-replace’ gene editing work | - |
| 13.07.2021 | Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing |
Show more